BCTX

BriaCell Therapeutics Corp. stock has experienced significant volatility over the past six months, with an 88.10% decline in share price as of May 5, 2026. Key events impacting the stock include a significant increase after reporting the sustained complete resolution of lung metastasis with Bria-OTS, clinical data presentations at ASCO 2026 and AACR Meeting, FDA clearance to initiate the Bria-BRES+™ Clinical Study, positive DSMB recommendations for the Phase 3 Bria-ABC study, preclinical data on Bria-OTS+™ anti-cancer activity, and an announcement of a share buyback.